FDA
-
-
-
-
-
-
-
Hims and Hers (HIMS) PT Raised to $36 at BofA Securities, 'This update is negative for the HIMS'
-
-
-
-
-
-
-
Hims & Hers earnings preview: BofA says company lost GLP-1 share in 1Q
-
-
-
-
-
-
-
Leerink Partners on Hims and Hers (HIMS): FDA meeting to discuss peptide restrictions 'clear positive,' could fill growth hole
-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Hims and Hers (HIMS)
-
-
-
-
-
-
-
Hims and Hers (HIMS) PT Lowered to $12.50 at BofA Securities
-
-
-
-
-
-
-
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Hims and Hers (HIMS)
-
334,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


